Luciferase Complementation Approaches to Measure GPCR Signaling Kinetics and Bias
- PMID: 34085274
- DOI: 10.1007/978-1-0716-1221-7_17
Luciferase Complementation Approaches to Measure GPCR Signaling Kinetics and Bias
Abstract
An understanding of the kinetic contributions to G protein-coupled receptor pharmacology and signaling is increasingly important in compound profiling. Nonequilibrium conditions are commonly present in vivo, for example, as the drug competes with dynamic changes in hormone or neurotransmitter concentration for the receptor. Under such conditions individual binding kinetic properties of the ligands can influence duration of action, local ligand concentration, and functional properties such as the degree of insurmountable inhibition. Mapping the kinetic patterns of GPCR signaling events elicited by agonists, rather than a peak response at a single timepoint, is often key to predicting their functional impact. This is also a path to a better understanding of the origins of ligand bias, and whether such ligands demonstrate their effects through selection of distinct GPCR conformations, or via their kinetic properties. Recent developments in complementation approaches, based on a small bright shrimp luciferase Nanoluc, provide a new route to kinetic analysis of GPCR signaling in living cells that is amenable to the throughput required for compound profiling. In the NanoBiT luciferase complementation system, GPCRs and effector proteins are tagged with Nanoluc fragments optimized for their low interacting affinity and stability. The interactions brought about by GPCR recruitment of the effector are reproduced by a rapid and reversible increase in NanoBiT luminescence, in the presence of its substrate furimazine. Here we discuss the methods for optimizing and validating the GPCR NanoBiT assays, and protocols for their application to study endpoint and kinetic aspects of agonist and antagonist pharmacology. We also describe how timecourse families of agonist concentration response curves, derived from a single NanoBiT assay experiment, can be used to evaluate the kinetic components in operational model derived parameters of ligand bias.
Keywords: Arrestin; Binding kinetics; G protein; G protein-coupled receptors; Ligand bias; Luciferase complementation; Operational model; Signaling kinetics.
Similar articles
-
A novel luminescence-based β-arrestin recruitment assay for unmodified receptors.J Biol Chem. 2021 Jan-Jun;296:100503. doi: 10.1016/j.jbc.2021.100503. Epub 2021 Mar 5. J Biol Chem. 2021. PMID: 33684444 Free PMC article.
-
NanoLuc-Based Methods to Measure β-Arrestin2 Recruitment to G Protein-Coupled Receptors.Methods Mol Biol. 2021;2268:233-248. doi: 10.1007/978-1-0716-1221-7_16. Methods Mol Biol. 2021. PMID: 34085273
-
The luminescent HiBiT peptide enables selective quantitation of G protein-coupled receptor ligand engagement and internalization in living cells.J Biol Chem. 2020 Apr 10;295(15):5124-5135. doi: 10.1074/jbc.RA119.011952. Epub 2020 Feb 27. J Biol Chem. 2020. PMID: 32107310 Free PMC article.
-
Luminescence- and Fluorescence-Based Complementation Assays to Screen for GPCR Oligomerization: Current State of the Art.Int J Mol Sci. 2019 Jun 17;20(12):2958. doi: 10.3390/ijms20122958. Int J Mol Sci. 2019. PMID: 31213021 Free PMC article. Review.
-
Recent progress in assays for GPCR drug discovery.Am J Physiol Cell Physiol. 2022 Aug 1;323(2):C583-C594. doi: 10.1152/ajpcell.00464.2021. Epub 2022 Jul 11. Am J Physiol Cell Physiol. 2022. PMID: 35816640 Review.
Cited by
-
Investigation of adenosine A1 receptor-mediated β-arrestin 2 recruitment using a split-luciferase assay.Front Pharmacol. 2023 May 30;14:1172551. doi: 10.3389/fphar.2023.1172551. eCollection 2023. Front Pharmacol. 2023. PMID: 37324481 Free PMC article.
-
Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors.Cell. 2023 Oct 26;186(22):4956-4973.e21. doi: 10.1016/j.cell.2023.09.020. Epub 2023 Oct 17. Cell. 2023. PMID: 37852260 Free PMC article.
-
GPCR binding and JNK3 activation by arrestin-3 have different structural requirements.bioRxiv [Preprint]. 2023 May 1:2023.05.01.538990. doi: 10.1101/2023.05.01.538990. bioRxiv. 2023. Update in: Cells. 2023 Jun 06;12(12):1563. doi: 10.3390/cells12121563. PMID: 37205393 Free PMC article. Updated. Preprint.
-
Arrestin-3 binds parkin and enhances parkin-dependent mitophagy.J Neurochem. 2025 Jan;169(1):e16043. doi: 10.1111/jnc.16043. Epub 2024 Jan 9. J Neurochem. 2025. PMID: 38196269
-
Quantifying the Kinetics of Signaling and Arrestin Recruitment by Nervous System G-Protein Coupled Receptors.Front Cell Neurosci. 2022 Jan 17;15:814547. doi: 10.3389/fncel.2021.814547. eCollection 2021. Front Cell Neurosci. 2022. PMID: 35110998 Free PMC article.
References
-
- Kenakin T (2019) Biased receptor signaling in drug discovery. Pharmacol Rev 71:267–315. https://doi.org/10.1124/pr.118.016790 - DOI - PubMed
-
- Stott LA, Hall DA, Holliday ND (2016) Unravelling intrinsic efficacy and ligand bias at G protein coupled receptors: a practical guide to assessing functional data. Biochem Pharmacol 101:1–12. https://doi.org/10.1016/j.bcp.2015.10.011 - DOI - PubMed
-
- Wootten D, Christopoulos A, Marti-Solano M et al (2018) Mechanisms of signalling and biased agonism in G protein-coupled receptors. Nat Rev Mol Cell Biol 19:638–653. https://doi.org/10.1038/s41580-018-0049-3 - DOI - PubMed
-
- Wingler LM, Elgeti M, Hilger D et al (2019) Angiotensin analogs with divergent bias stabilize distinct receptor conformations. Cell 176:468–478.e11. https://doi.org/10.1016/j.cell.2018.12.005 - DOI - PubMed - PMC
-
- Masureel M, Zou Y, Picard L-P et al (2018) Structural insights into binding specificity, efficacy and bias of a beta2AR partial agonist. Nat Chem Biol 14:1059–1066. https://doi.org/10.1038/s41589-018-0145-x - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources